Sesen Bio (SESN) Misses Q3 EPS by 11c

Sesen Bio (NASDAQ: SESN) reported Q3 EPS of ($0.19), $0.11 worse than the analyst estimate of ($0.08).

“We are rapidly advancing toward the finalization of our BLA in December as well as a potential MAA submission in Europe in early 2021,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “We believe the probability of regulatory success is high in both the US and Europe due to the strong clinical profile of Vicineum enabled by the unique dual mechanism of action. Once approved, we think Vicineum has the potential to be the best-in-class therapeutic in BCG-unresponsive NMIBC with a significant global commercial opportunity. We remain laser-focused towards executing on upcoming key milestones to the benefit of both patients and shareholders.”

For earnings history and earnings-related data on Sesen Bio (SESN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Z Squared outlines AI power strategy and Paradox Data acquisition
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15